ARTICLE | Clinical News
MTR106: Phase II data
November 12, 2007 8:00 AM UTC
In a double-blind, placebo-controlled Phase II trial in 40 female patients with migraine without aura, all 4 doses of MTR106 (25, 50, 75 and 100 mg) met the primary endpoint of superiority to placebo ...